Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1041-1060 of 3,900 trials

Metastatic Colorectal Cancer: Atezolizumab with FOLFOXIRI

We are studying whether adding Atezolizumab to standard treatment helps patients with unresectable metastatic colorectal cancer live longer without disease progression. The trial also looks at the safety and quality of life for participants.

Metastatic Colorectal Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Rheumatoid Arthritis: Rituximab Tapering Strategies

We are studying different ways to reduce rituximab doses in patients with rheumatoid arthritis. The goal is to find the best method to lower disease impact and activity.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Pulmonary Sarcoidosis: OATD-01 Treatment Study

We are studying the effects of OATD-01, an oral medication, on reducing lung inflammation in people with active pulmonary sarcoidosis. The trial will also look at safety, lung function, and quality of life.

Pulmonary Sarcoidosis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Graft-Versus-Host Disease Prevention in Elderly Cancer Patients

We are studying whether a low dose of a specific medication can help prevent complications in elderly patients with blood cancers receiving stem cell transplants. This trial aims to improve recovery and overall outcomes after the transplant.

Blood Cancers>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Non-Hodgkin Lymphoma: BMS-986458 Treatment Study

We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Ocular Myasthenia Gravis: Corticosteroids and Rituximab Treatment

We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.

Myasthenia Gravis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyRheumatology

HER2-Positive Gastric Cancer: New Treatment Study

We are testing a new combination of medications for patients with HER2-positive gastric or gastroesophageal cancer. The goal is to see if it helps clear cancer markers and improves survival compared to standard chemotherapy.

Gastric or Gastroesophageal Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Idiopathic Hypersomnia: Melatonin and Light Therapy Study

We are investigating whether a combination of evening melatonin and morning light therapy can help adults with idiopathic hypersomnia feel less sleepy. This study compares the treatment to a placebo to see if it makes a difference.

Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rheumatoid Arthritis: New Biosimilar Drug Study

We are comparing a new biosimilar drug to Orencia® for patients with moderate to severe rheumatoid arthritis already taking methotrexate. The study will look at effectiveness, safety, and how the body reacts to the treatment.

Rheumatoid Arthritis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Multiple Myeloma: Etentamig Treatment Study

We are studying a new medication, Etentamig, for adults with relapsed or refractory multiple myeloma who have already received multiple treatments. The goal is to see if it is more effective and safe compared to standard therapies.

Relapsed or Refractory Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Heart Failure: Colchicine and Thiamine Study

We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.

Heart Failure>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Localized Ocular Melanoma: IDE196 Treatment Study

We are testing the investigational drug IDE196 to see if it can shrink tumors in patients with localized ocular melanoma before surgery. The study aims to evaluate its safety and effectiveness in improving treatment outcomes.

Uveal MelanomaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOphthalmology

Metastatic Uveal Melanoma: IDE196 and Crizotinib Combination

We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.

Uveal Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Fertility Treatments: Comparing Ovarian Stimulation Methods

We are studying two ovarian stimulation methods to see which one improves quality of life and satisfaction for women seeking fertility preservation or genetic testing. This research aims to help tailor treatments based on individual needs.

Subfertility3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Non-Small Cell Lung Cancer: Tiragolumab and Atezolizumab Study

We are evaluating the safety of a new treatment combining tiragolumab and atezolizumab for patients with certain stages of non-small cell lung cancer after surgery and chemotherapy. This study compares it to a placebo treatment to see how well it works.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Oncology

Prostate Cancer: 12-Month Treatment Study

We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.

Low-Volume Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

HER2-Low Breast Cancer: Trastuzumab-Deruxtecan Study

We are studying a new treatment for patients with HER2-low breast cancer and brain metastases to see if it helps shrink tumors and improve quality of life. This trial will also look at safety and how well patients tolerate the treatment.

HER2-Low Breast Cancer with Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Rectal Cancer Treatment: Comparing Therapies for Older Patients

We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.

Rectal Cancer6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Crohn's Disease: TAK-279 Oral Medication

We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Aggressive Large B-Cell Lymphoma: Golcadomide After CAR T-Cell Therapy

We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.

Aggressive Large B-Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology